128 related articles for article (PubMed ID: 30733274)
1. Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia.
Abboud R; Han SY; Duncavage EJ; Cashen AF; Shirai CL; Welch JS; DiPersio JF; Abboud CN
Haematologica; 2019 Apr; 104(4):e170-e173. PubMed ID: 30733274
[No Abstract] [Full Text] [Related]
2. Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
Wang A; Cai X; Qiang P; Duan Q
Leuk Lymphoma; 2018 Mar; 59(3):763-765. PubMed ID: 28760054
[No Abstract] [Full Text] [Related]
3. Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia.
Heiblig M; Paubelle E; Plesa A; Geay MO; Manzoni D; Gazzo S; Tigaud I; Callet-Bauchu E; Huet S; Salles G; Thomas X; Hayette S; Sujobert P
Blood; 2017 Jan; 129(1):128-131. PubMed ID: 27827828
[No Abstract] [Full Text] [Related]
4. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.
Castelli R; Rossi V; Della Porta MG; Schiavon R; Barchiesi M; Cicconi L; Coco FL
Ann Hematol; 2018 Dec; 97(12):2523-2525. PubMed ID: 29872883
[No Abstract] [Full Text] [Related]
7. Current treatment of acute promyelocytic leukemia.
Lo Coco F; Ammatuna E; Sanz MA
Haematologica; 2007 Mar; 92(3):289-91. PubMed ID: 17339175
[No Abstract] [Full Text] [Related]
8. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
9. Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
George B; Mathews L; Balasubramanian P; Shaji RV; Srivastava A; Chandy M
Haematologica; 2004 Oct; 89(10):1266-7. PubMed ID: 15477216
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
Ha JS; Do YR; Ki CS; Lee C; Kim DH; Lee W; Ryoo NH; Jeon DS
Leukemia; 2017 Sep; 31(9):1992-1995. PubMed ID: 28555082
[No Abstract] [Full Text] [Related]
12. Morphologic heterogeneity of acute promyelocytic leukemia: therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology.
Sinha S; Aish L; Oo TH
Am J Hematol; 2006 Jun; 81(6):475-6. PubMed ID: 16680741
[No Abstract] [Full Text] [Related]
13. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
George B; Poonkuzhali B; Srivastava VM; Chandy M; Srivastava A
Ann Hematol; 2005 Jun; 84(6):406-8. PubMed ID: 15592671
[TBL] [Abstract][Full Text] [Related]
14. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Grimwade D; Jovanovic JV; Hills RK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
[TBL] [Abstract][Full Text] [Related]
15. [All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect].
Kitamura K; Takeshita A; Ono R; Naoe T
Rinsho Ketsueki; 1996 Sep; 37(9):760-5. PubMed ID: 8914458
[No Abstract] [Full Text] [Related]
16. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring of minimal residual disease in patients with acute promyelocytic leukemia].
Shuravina EN; Parovichnikova EN; Demidova IA; Misiurin AV; Isaev VG; Ol'shanskaia IuV; Savchenko VG
Ter Arkh; 2006; 78(7):25-31. PubMed ID: 16944747
[TBL] [Abstract][Full Text] [Related]
18. PML/RAR alpha(+) hypergranular acute promyelocytic leukemia (M3) developing into an M3 acute myelocytic leukemia without PML/RAR alpha.
Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Reyes-Núñez V
Acta Haematol; 2000; 104(2-3):124-7. PubMed ID: 11154988
[TBL] [Abstract][Full Text] [Related]
19. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
Coombs CC; Mathews SP
Am J Hematol; 2018 Aug; 93(4):595-596. PubMed ID: 29052253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
